Bevacizumab Biosimilars Reduce Costs While Maintaining Survival Outcomes in mCRC

April 02, 2025

Bevacizumab biosimilars Mvasi and Zirabev provided cost savings for metastatic colorectal cancer (mCRC) treatment without compromising effectiveness.

Biosimilars Gastroenterology Roundup: March 2025
Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
The Top 5 Biosimilar Articles for the Week of March 24